Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis.

PloS one - 1 Jan 2022

Meng Guangxian, Liu Xiaowei, Ma Tian, Lv Desheng, Sun Ge

Abstract excerpt

BACKGROUND: Immunotherapy has emerged as a promising treatment for non-small cell lung cancer (NSCLC). Yet, some patients cannot benefit from immunotherapy, and reliable biomarkers for selecting sensitive patients are needed. Herein, we performed a meta-analysis to evaluate the predictive value of tumor mutational burden (TMB) in NSCLC patients treated with immunotherapy. METHODS: Eligible studies were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunologic Factors

Share to Immunotherapy

Share to Odds Ratio

Share to Predictive Value of Tests

Share to Progression-Free Survival

Share to Proportional Hazards Models

Source

Open in PubMed Open full text

Identifiers

PMID: 35113949
DOI: 10.1371/journal.pone.0263629
PMCID: PMC8812984

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis.PMID 35113949Read ↗

The Predictive efficacy of tumor mutational burden for immune Checkpoint Inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trialsSemantic proximity Read ↗

Prognostic value of tumor mutation burden in non-small cell lung cancer: A Meta-Analysis and system reviewSemantic proximity Read ↗

The association of efficacy with PD-1/PD-L1 inhibition and tumor mutational burden in advanced nonsmall cell lung cancer: A PRISMA-guided literature review and meta-analysis.Semantic proximity Read ↗

Predictive value of tumor mutational burden for PD-1/PD-L1 inhibitors in NSCLC: A meta-analysis.Semantic proximity Read ↗

Tumor mutational burden and efficacy of chemotherapy in lung cancer.Semantic proximity Read ↗

Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.Semantic proximity Read ↗

The landscape of tumor mutational burden and its clinical significance in patients with lung cancer: a Multi-omics study with a meta-analysisSemantic proximity Read ↗

Efficacy and safety of immunotherapy in driver mutation-negative advanced non-small cell lung cancer: A systematic review and meta-analysis.Semantic proximity Read ↗

Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers.Semantic proximity Read ↗

Higher Tumor Mutation Burden Was a Predictor for Better Outcome for NSCLC Patients Treated with PD-1 Antibodies: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker.Semantic proximity Read ↗

A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid Tumours.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.